SCHEMBL7127463

SCHEMBL7127463

Cn1cncc1-c1cccc(Nc2nnc3c4c(cccc24)-c2ccccc2-3)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.43
KDR P35968 4/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
PDE5A O76074 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
CYP2C19 P33261 1/20 0.41
PDE1A P54750 1/20 0.41
PDE1B Q01064 1/20 0.41
PDE3B Q13370 1/20 0.41
PDE1C Q14123 1/20 0.41
PDE3A Q14432 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128067 0.82 ALDH1A1 (0.43) KDRMAPTALDH1A1KDM4EPDE5A
SCHEMBL7117372 0.75 AHR (0.47) KDRMAPTALDH1A1KDM4EPDE5A
SCHEMBL7121980 0.74 IDO1 (0.46) IDO1HPGDSRIPK2TTKHTR2C
SCHEMBL7123001 0.72 ABL1 (0.42) IDO1KDRMAPTALDH1A1KDM4E
SCHEMBL7124221 0.67 IDO1 (0.48) IDO1HPGDSTTK
Iodide SCHEMBL7122705 0.67 MAPT (0.40) KDRMAPTALDH1A1KDM4EPDE5A
SCHEMBL21128683 0.66 IDO1 (0.68) IDO1KDRHPGDSPRKDCHTR2C
SCHEMBL30473398 0.64 IDO1 (0.66) IDO1HPGDSPRKDCTTKLDLR
SCHEMBL7128025 0.64 IDO1 (0.66) IDO1HPGDSPRKDCTTKLDLR
SCHEMBL7122983 0.63 AURKA (0.43) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 IDO1 1301/4885KDR 1404/4885MAPT 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.